Amprenavir

Routes of
administrationOral (capsules)ATC codeLegal statusLegal status Pharmacokinetic dataProtein binding90%MetabolismHepaticElimination half-life7.1–10.6 hoursExcretion<3% renalIdentifiersCAS NumberPubChem CIDDrugBankChemSpiderUNIIKEGGChEBIChEMBLNIAID ChemDBCompTox Dashboard (EPA)ECHA InfoCard100.262.589 Chemical and physical dataFormulaC₂₅H₃₅N₃O₆SMolar mass505.63 g·mol⁻¹3D model (JSmol)  (verify)

Amprenavir (original brand name Agenerase, GlaxoSmithKline) is a protease inhibitor used to treat HIV infection. It was approved by the Food and Drug Administration on April 15, 1999, for twice-a-day dosing instead of needing to be taken every eight hours. The convenient dosing came at a price, as the dose required is 1,200 mg, delivered in 8 (eight) very large 150 mg gel capsules or 24 (twenty-four) 50 mg gel capsules twice daily.^[1]

It was patented in 1992 and approved for medical use in 1999.^[2] Production of amprenavir was discontinued by the manufacturer on December 31, 2004; a prodrug version (fosamprenavir), is available.

Background

Research aimed at development of renin inhibitors as potential antihypertensive agents had led to the discovery of compounds that blocked the action of this peptide cleaving enzyme. The amino acid sequence cleaved by renin was found to be fortuitously the same as that required to produce the HIV peptide coat. Structure–activity studies on renin inhibitors proved to be of great value for developing HIV protease inhibitors. Incorporation of an amino alcohol moiety proved crucial to inhibitory activity for many of these agents. This unit is closely related to the one found in the statine, an unusual amino acid that forms part of the pepstatin, a fermentation product that inhibits protease enzymes.^{[citation needed]}

References

External links

• Amprenavir bound to proteins in the Protein Data Bank